HANXBIO-B (03378) will present four poster research findings at the AACR Annual Meeting in 2026.

HANXBIO-B(03378) announced that the research results of four innovative drugs will be presented in poster form at the American Association for Cancer Research (AACR) Annual Meeting in 2026. The AACR Annual Meeting will be held from April 17-22, 2026 at the San Diego Convention Center in California, USA. The selection of these results further validates the company's research and development capabilities and innovative abilities. 1. HX044 poster presentation HX044 is a global innovative CTLA-4/SIRP dual-function fusion protein, the next generation CTLA-4 targeted therapy that enhances the elimination of regulatory T-cells in the tumor microenvironment by targeting both CTLA-4 and CD47 simultaneously to reduce immune suppression of tumors and enhance anti-tumor activity. Its main development direction is PD-1/ICI-resistant solid tumors, forming a synergistic and complementary tumor immune pipeline layout with the company's HX009. 2. HX116 poster presentation HX116 is a potential first-in-class Bispecific Antibody Drug Conjugate (BsAbADC) developed independently by the company, targeting PD-(L)16VEGF, and introducing additional modes of action (such as direct killing and enhanced tumor immune cell death) to increase anti-tumor activity, potentially having great market potential. In preclinical studies, HX116 showed greater activity than its parent BsAb. 3. HX112 poster presentation HX112 is a novel PD-L1 targeted ADC developed independently by the company, intended for pan-solid tumor therapy. 4. 3D Tumor Organ ADC Evaluation System poster presentation This study presents the company's innovative ADC preclinical evaluation system, validating that 3D tumor organ models can better predict in vivo anti-tumor effects compared to 2D cell models.